| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HDAC7A |
| Uniprot No | Q8WUI4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 645-915aa |
| 氨基酸序列 | VTDLAFKVASRELKNGFAVVRPPGHHADHSTAMGFCFFNSVAIACRQLQQQSKASKILIVDWDVHHGNGTQQTFYQDPSVLYISLHRHDDGNFFPGSGAVDEVGAGSGEGFNVNVAWAGGLDPPMGDPEYLAAFRIVVMPIAREFSPDLVLVSAGFDAAEGHPAPLGGYHVSAKCFGYMTQQLMNLAGGAVVLALEGGHDLTAICDASEACVAALLGNRVDPLSEEGWKQKPNLNAIRSLEAVIRVHSKYWGCMQRLASCPDSWVPRVPGA |
| 分子量 | 33.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Expression and Purification of Recombinant Human HDAC7A for Structural Studies"**
*Author: Zhang, L., et al.*
摘要：该研究报道了在大肠杆菌系统中高效表达并纯化重组人HDAC7A蛋白的方法，通过X射线晶体学解析其三维结构，揭示了催化活性位点的关键氨基酸残基。
2. **"HDAC7A Regulates Endothelial Cell Migration via Deacetylation of β-Catenin"**
*Author: Wilson, J.E., & Chang, T.H.*
摘要：研究利用重组HDAC7A蛋白验证其在内皮细胞迁移中的作用，发现其通过去乙酰化β-catenin调控Wnt信号通路，影响血管生成。
3. **"Development of a High-Throughput Assay for HDAC7A Inhibitor Screening"**
*Author: Gupta, R., et al.*
摘要：开发了基于重组HDAC7A酶活性的高通量抑制剂筛选平台，筛选出多个小分子化合物，为靶向HDAC7A的疾病治疗提供候选药物。
4. **"HDAC7A Modulates Myogenic Differentiation through Interaction with MEF2 Transcription Factors"**
*Author: Miyazawa, K., & Yoshida, M.*
摘要：研究发现重组HDAC7A通过结合MEF2转录因子调控肌肉细胞分化，去乙酰化作用影响染色质重塑及靶基因表达。
(注：以上文献为假设示例，实际引用需查询真实数据库。)
Histone deacetylase 7A (HDAC7A), a member of the class IIa HDAC family, is a chromatin-modifying enzyme critical for regulating gene expression and cellular processes. HDACs catalyze the removal of acetyl groups from lysine residues on histones, promoting chromatin condensation and transcriptional repression. HDAC7A uniquely combines enzymatic activity with non-enzymatic scaffolding functions, interacting with transcription factors like MEF2 and FOXP3 to modulate cell differentiation, metabolism, and immune responses. It plays key roles in vascular development, T-cell regulation, and muscle homeostasis.
Recombinant human HDAC7A protein is typically produced in heterologous expression systems (e.g., E. coli or insect cells) with purification tags (e.g., His-tag) to facilitate biochemical studies. Its structure contains an N-terminal regulatory domain for protein interactions and a C-terminal catalytic domain requiring Zn²⁺ for deacetylase activity. Unlike class I HDACs, HDAC7A's enzymatic activity is relatively weak and context-dependent, suggesting its primary functions may involve recruiter roles for other HDAC complexes.
Research on recombinant HDAC7A focuses on unraveling its dual roles in gene regulation, connection to cancers (e.g., leukemia, solid tumors), and metabolic disorders. It serves as a tool for drug discovery, particularly for developing isoform-selective HDAC inhibitors with reduced side effects compared to pan-HDAC blockers.
×
